to evaluate the efficacy and safety of anrotinib hydrochloride capsule in postoperative non-pcr patients with non-small cell lung cancer

Conditions: Event-free Lifetime

Summary: to explore the effectiveness of anrotinib hydrochloride capsule in postoperative non-pcr non-small cell lung cancer patients with adjuvant intensive therapy


Eligibility criteria:
inclusion criteria: 1. the subjects voluntarily joined the study, signed the informed consent, and the compliance was good; 2. ≥18 years old (calculated by the date of signing the informed consent); both men and women; ecog score 0\~1; expected survival ≥3 months; 3. patients with stage iia-iiia nsclc who had previously received pd-1/pd-l1 inhibitors combined with chemotherapy neoadjuvant therapy and underwent r0 resection for curative purposes before surgery (note: the disease was presented in the american joint committee on cancer (ajcc)/union international against cancer (uicc) 8th edition of lung cancer tnm staging); 4. for patients who did not achieve pathological complete response after pd-1/pd-l1 inhibitor combined with chemotherapy neoadjuvant treatment, and the time between the first trial medication after surgery was required to be 4-12 weeks; 5. the main organs function well and meet the standards; 6. women of reproductive age should agree that effective contraception must be used during the study period and for 6 months after the end of the study, and that serum or urine pregnancy tests are negative within 7 days prior to study enrollment; men should agree that effective birth control must be used during the study period and for 6 months after the end of the study period. exclusion criteria: 1. have had or are currently suffering from other malignant tumors within 5 years. the following two conditions can be included: other malignancies treated with a single operation, achieving continuous 5-year disease-free survival (dfs); cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors \[ta (non-invasive tumor), tis (cancer in situ) and t1 (tumor infiltrating basal membrane)\]; 2. subjects are known to have genetic abnormalities that have been approved for targeted drug therapy (non-squamous cell carcinoma subjects are required to have egfr or alk gene tested or provide previous test reports during the screening period) 3. cardiovascular and cerebrovascular abnormalities: 1. patients with past or existing heart failure, degree ii or higher heart block; 2. past or present myocardial infarction or unstable angina pectoris, clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; 3. occurrence of arteriovenous thrombosis/cancer embolus events within 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction requiring clear diagnosis), vascular embolism (including deep vein thrombosis, arterial thrombosis, pulmonary embolism, etc.); 4. participated in other drug clinical trials within the past 30 days; 5. within 2 weeks before starting the administration, it has been treated with chinese patent medicines (including compound cantharides capsule, kangai injection, kanglaite capsule/injection, aidi injection, bruceae oil injection/capsule, xiaoaipingtablet/injection, hualbufatin capsule, etc.) with anti-tumor indications specified in the nmpa approved drug instructions; 6. received major surgery other than radical resection of lung cancer within 4 weeks prior to initiation of administration; according to the investigator, the patient was not eligible to participate in this clinical study for other reasons.